Schizophrenia: Addressing the Burden of Relapse Through Improved Adherence

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Jan 6, 2016          Expiration Date: Jan 6, 2017

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.


Download (PDF) Click here to download a PDF of the program slides.


Despite recent advances in the understanding and management of schizophrenia, it remains a chronic relapsing and remitting disorder associated with significant impairments in social and vocational functioning, as well as a shortened lifespan. Many patients experience ongoing relapses and rehospitalizations, which impose a considerable drain on healthcare resources. In September 2014, the Agency for Healthcare Research and Quality stated that “Repeated hospitalizations on a psychiatric unit, affecting primarily the seriously mentally ill, are a substantial problem.” Between 40%-50% of patients with a history of psychiatric hospitalizations are readmitted within 12 months. In response, several agencies and health insurances have developed quality measures related to schizophrenia, such as reductions in hospital re-admissions and ensuring continuity of care. Reimbursements and payments to clinicians are directly affected by their reporting on these measures.

Patient adherence to treatment is among the most important predictors of relapse, and data show that even short gaps in adherence are associated with increased risk of hospitalization. The National Committee for Quality Assurance and Healthcare Effectiveness Data and Information Set (HEDIS) developed a measure specifically looking at the proportion of schizophrenia patients who were adherent to antipsychotic medications, placing pressure on clinicians to detect, address, or (best of all) prevent non-adherence in their patients.

This CME certified activity will deliver state-of-the-art information to enable psychiatrists and other members of the care team to satisfactorily perform to quality measures, reduce hospital re-admissions, ensure continuity of care, and enhance patient adherence to treatment regimens.  


Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY

Read Biography


The target audience for this initiative includes psychiatrists and other health care providers who care for patients with schizophrenia.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Explain the magnitude of the problem of low adherence in persons with schizophrenia and its impacts on long-term outcomes and rehospitalizations, as well as the need for a proactive approach to prevent and detect nonadherence to treatments
  • Identify evidence-based data and tools, including new features from the DSM-5, into daily practice to assess treatment response and adjust therapy as needed to improve outcomes
  • Assess the health and cost impacts of long-acting injectable antipsychotics for the management of schizophrenia, and determine their role in addressing patient barriers to adherence


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    PHYSICIAN CREDIT Designation

    The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits TM.  Physicians should claim only the credits commensurate with the extent of their participation in the activity.

    For questions regarding CME credit, the post-test, evaluation, please email


    Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

    All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

    The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

    The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Leslie Citrome, MD, MPH: Consultant/Independent Contractor: Alexza, Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, Vanda; Speaker’s Bureau: Alkermes, Allergan, AstraZeneca, Janssen, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva; Stock Shareholder (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer

    Non-faculty Disclosures

    Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

    Carole Drexel, PhD, CHCP; Blair St. Amand; Jay Katz, CHCP; Ashley Marostica, RN, MSN: Nothing to disclose.


    The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


    In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.


    There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.25 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test three times.


    Jointly provided by Potomac Center for Medical Education and Rockpointe




    This activity is supported by an independent educational grant from Alkermes, Inc.

    By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.